PCBL arm Nanovace Tech secures US patent for next-gen energy storage nanomaterials
The patent marks a significant milestone in the company's R&D efforts, bolstering its intellectual property portfolio in the energy storage space, according to a regulatory filing.
Kolkata, Jul 21 (PTI) Nanovace Technologies Ltd, a subsidiary of PCBL Chemical Ltd, on Monday said it has secured a patent from the US for its proprietary method of developing nanomaterials targeted at next-generation energy storage technologies.
Nanovace is currently constructing a pilot plant at PCBL's Palej site in Gujarat, expected to be ready by the third quarter of FY'26, to demonstrate the industrial scalability of the patented technology.
PCBL Chemical holds a 51 per cent stake in Nanovace Technologies, while the remaining 49 per cent is owned by Kindia Private Ltd.
The joint venture focuses on developing nanosilicon materials for use in lithium-ion battery anodes.
PCBL, in the past, said it was planning to invest USD 44 million in Nanovace, aimed at acquiring intellectual property, establishing the pilot plant, and subsequently setting up a commercial-scale manufacturing facility. PTI BSM BDC
This report is auto-generated from PTI news service. ThePrint holds no responsibility for its content.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
17 minutes ago
- Hindustan Times
How much cheaper will whiskey be after India-UK FTA? What experts said
The India-United Kingdom free trade agreement is expected to lower import duties on spirits, potentially making premium international liquor brands more affordable for Indian consumers. The International Spirits and Wines Association of India (ISWAI) hailed the trade deal as a historic moment for the alcoholic beverage sector.(Representational Image) However, experts have cautioned that the impact may be modest, with price reductions likely capped at around ₹300 per bottle. India and the UK signed a historic bilateral Free Trade Agreement (FTA) on Thursday. The pact will boost bilateral commerce by $35 billion in the long run. The India-UK FTA was finalised in May after more than three years of negotiations and was signed by commerce minister Piyush Goyal and his UK counterpart Jonathan Reynolds during Prime Minister Narendra Modi's visit to Britain. As per the FTA signed in London between the two governments, India is reducing duty on UK whisky and gin from 150 per cent to 75 per cent and further to 40 per cent in the 10th year of the deal. Also Read | India, Britain seal trade deal to bring down tariffs, barriers; keep dairy out "Whisky producers will benefit from tariffs slashed in half, reduced immediately from 150 per cent to 75 per cent and then dropped even further to 40 per cent over the next ten years - giving the UK an advantage over international competitors in reaching the Indian market," as per an official statement of the UK government. What experts said The International Spirits and Wines Association of India (ISWAI), which represents premium alcoholic beverage companies in India (mostly MNCs), hailed the trade deal as a historic moment for the alcoholic beverage sector. 'The deal will significantly benefit Indian consumers, as premium international spirits will become more accessible, thereby accelerating the ongoing trend of premiumisation,' ISWAI CEO Sanjit Padhi was quoted as saying by PTI. "It will also stimulate growth across ancillary sectors, such as hospitality, tourism, and retail, while potentially increasing the revenue for Indian states." Also Read | Visa, employment, insurance: What will change for Indians in UK under trade deal Industry experts, however, opined that while companies could benefit end-consumers, there would be very few benefits in terms of price reduction. 'Consumer prices for imported Scotch (whiskey) are not likely to change much,' liquor industry expert Vinod Giri said, according to PTI. "Most of the taxes on alcohol sit in states, and even if all customs duty reduction is passed on, the impact on consumer prices of imported Scotch whiskies will be in the range of ₹100-300 per bottle," he added.
Time of India
an hour ago
- Time of India
72% of DU students back fourth year under NEP 2020's FYUP, opt-out open till August 1
NEW DELHI: In an endorsement of Delhi University 's Four-Year Undergraduate Programme (FYUP) under NEP 2020, nearly 72 per cent of eligible students have chosen to continue with the fourth year, Vice Chancellor Yogesh Singh said on Thursday. The university has kept the option to opt-out of the fourth year open until the commencement of the new academic session on August 1. "As of now, 20,221 students out of over 72,000 students have opted out, which means more than 50,000 students are continuing. This is very encouraging and shows students see value in opting the fourth year," Singh told media. The fourth year will commence across all Delhi University colleges from August 1. The FYUP, implemented under the National Education Policy (NEP) 2020, offers multiple exit points -- certificate after one year, diploma after two and a degree after three years. Students completing the fourth year are awarded an Honours with Research degree, with an added emphasis on research, entrepreneurship and skill-based learning. In an interview with PTI in May, Singh had called the fourth year a "game changer." by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like American Investor Warren Buffett Recommends: 5 Books For Turning Your Life Around Blinkist: Warren Buffett's Reading List Undo "This is the first time the focus is on research, entrepreneurship and skill... this fourth year will be a game changer," he had said. However, teachers' associations and educationists remain skeptical, with several pointing out that the restructured programme may lead to increased dropout rates, as students are unclear about the value and content of the fourth year. There are also concerns about overburdened faculty and limited funding for essential upgrades. Amid these infrastructure concerns, Singh said the university is committed to addressing them. "Don't worry. If facilities are not available, they will be created. It is in the interest of our students," he had said. With just a week remaining, Delhi University faces the challenge of addressing these logistical and academic gaps. The coming time will be crucial in determining whether the ambitious overhaul will fulfil its promise of transforming undergraduate education or falter under unpreparedness. Ready to navigate global policies? Secure your overseas future. Get expert guidance now!
Indian Express
2 hours ago
- Indian Express
India-UK trade deal: Will export volume of Indian medical devices go up?
Indian Prime Minister Narendra Modi and UK Prime Minister Keir Starmer signed the India-UK free trade agreement on Thursday, allowing wider access to Indian exports in the UK markets. Pharmaceuticals and medical devices will enjoy zero-duty access under this agreement. With most pharmaceuticals and medical devices exported to the UK already being duty-free, industry experts say easing regulatory norms are likely to have a bigger impact in facilitating Indian exports to the UK. What does the trade deal say about the drugs and medical devices sector? The zero-tariff provisions are likely to make Indian generic medicines more cost-effective in the UK market, as per the agreement. 'India exports USD 23.31 billion globally and the UK imports nearly USD 30 billion, but Indian pharma accounts for under USD 1 billion, indicating significant headroom for growth,' the sectoral outcome summary states. When it comes to medical devices, the agreement says that surgical instruments, diagnostic equipment, ECG machines, X-Ray systems among others will not attract any duty. 'This will reduce costs for Indian med-tech companies and make their products more competitive in the UK market,' the agreement says. The agreement adds that India has emerged as a cost-effective alternative to China, given that the UK is trying to move away from reliance on Chinese imports after Brexit and Covid-19. The agreement says: 'Indian manufacturers are poised to emerge as a favoured, cost-effective alternative, especially with zero-duty pricing for medical devices.' What do Indian manufacturers have to say? When it comes to pharmaceuticals, the agreement is unlikely to lead to a sudden, sharp increase in Indian exports to the UK. An industry expert, who did not want to be named, said, 'The pharmaceutical industry is likely to continue growing at its current trajectory — at around 10 per cent every year — because most of the drugs were already exempt from duty in the UK. What will help is easing of the regulatory framework, which will allow more Indian companies to enter the UK market and quickly.' Companies may end up spending thousands of dollars in getting the requisite approvals to sell in the UK. The same is true for medical devices as well. Rajiv Nath, forum coordinator of Association of Indian Medical Device Industry (AiMeD), said, 'Medical devices imported from India by UK were duty-free previously as well, so tariff restrictions were not an issue. It was the time and cost of regulatory approvals that were a challenge.' He added that the industry had previously sought the recognition of approvals granted by the country's apex drug regulator, CDSCO, or voluntary Quality Control of India certification for fast-tracking regulatory approvals in the UK. Nath added that the lowering of the 7.5 per cent duty levied by India on most UK manufactured medical devices would hopefully happen in a phased manner. He added another caution: 'There is a need for strict verification of the rules of origin of the medical devices in order to ensure that products manufactured by a third country are not routed through the UK for the tariff benefit. This is to ensure that India's nascent medical device industry remains competitive.' How many pharmaceutical products does the UK import from India? UK is the second largest importer of Indian pharmaceutical products, having purchased goods worth USD 913.97 million in FY2025. The country accounted for three per cent of all pharmaceutical exports from India. The largest importer of Indian pharmaceuticals continues to be the US, accounting for 34.5 per cent of the total exports, amounting to USD 10,515 million. The most commonly exported products from India are generic versions of small-molecule pills as well as biologicals (medicines derived from living organisms or cells). What's the quantum of medical devices that the UK imports from India? Export of Indian medical devices to the UK went up by 13 per cent in FY24 as compared to the previous year. These devices were worth Rs 1,015 crore, up from Rs 897.4 crore the previous year. The most common exports to the UK were contact lenses, diagnostic reagents, surgical instruments and PPE kits. Anonna Dutt is a Principal Correspondent who writes primarily on health at the Indian Express. She reports on myriad topics ranging from the growing burden of non-communicable diseases such as diabetes and hypertension to the problems with pervasive infectious conditions. She reported on the government's management of the Covid-19 pandemic and closely followed the vaccination programme. Her stories have resulted in the city government investing in high-end tests for the poor and acknowledging errors in their official reports. Dutt also takes a keen interest in the country's space programme and has written on key missions like Chandrayaan 2 and 3, Aditya L1, and Gaganyaan. She was among the first batch of eleven media fellows with RBM Partnership to End Malaria. She was also selected to participate in the short-term programme on early childhood reporting at Columbia University's Dart Centre. Dutt has a Bachelor's Degree from the Symbiosis Institute of Media and Communication, Pune and a PG Diploma from the Asian College of Journalism, Chennai. She started her reporting career with the Hindustan Times. When not at work, she tries to appease the Duolingo owl with her French skills and sometimes takes to the dance floor. ... Read More
